Ectica Technologies
Private Company
Funding information not available
Overview
Ectica Technologies is a privately held spin-off from ETH Zurich and the University of Zurich, founded to commercialize innovative hydrogel technologies for pre-clinical drug discovery. The company's patented 3DProSeed® platform creates synthetic, animal-free models of the tumor stroma, addressing the critical need to incorporate tumor-stroma interactions into high-content screening assays. By providing physiologically relevant yet automation-compatible models, Ectica targets the growing demand for more predictive in vitro systems in oncology and fibrosis research. Its business model combines product sales (StromaLine models) with contract development and manufacturing services for tailored hydrogel formulations.
Technology Platform
Patented 3DProSeed® synthetic hydrogel platform using electrochemical control of enzymatic reactions to create precisely engineered, animal-free 3D cell culture models that replicate the tumor stroma and tissue microenvironment for drug screening.
Opportunities
Risk Factors
Competitive Landscape
Ectica competes in the 3D cell culture and complex in vitro models market against companies offering organoid technologies, natural matrix products (e.g., Corning's Matrigel), and other synthetic hydrogel providers. Its differentiation lies in its patented electrochemical control for manufacturing and its specific focus on engineered, reproducible tumor stroma models compatible with high-throughput screening.